Isoeugenodilol: A vasorelaxant ?/?-adrenoceptor blocker with antioxidant activity (2000)

Isoeugenodilol, derived from isoeugenol, was investigated under in vivo and in vitro conditions. Isoeugenodilol (0.1, 0.5, 1.0, and 3.0 mg kg–1, i.v.) produced dose-dependent hypotensive and bradycardia responses in pentobarbital-anesthetized Wistar rats. Isoeugenodilol (0.5 mg kg–1, i.v.) also markedly inhibited both the tachycardia effects induced by (-) isoproterenol and arterial pressor responses induced by phenylephrine. A single oral administration of isoeugenodilol at doses of 10, 30, and 100 mg kg–1 dose-dependently reduced blood pressure, with a decrease in heart rate in conscious spontaneously hypertensive rats (SHRs). In the isolated Wistar rat right atria, left atria, and guinea pig tracheal strips, isoeugenodilol competitively antagonized the (-) isoproterenol-induced positive chronotropic effects, inotropic effects, and tracheal relaxation effects in a concentration-dependent manner. The parallel shift to the right of the concentration–response curve of (-) isoproterenol suggested that isoeugenodilol was a β1/β2-adrenoceptor competitive antagonist. The apparent pA2 values were 7.33 ± 0.12 in the right atria, 7.80 ± 0.09 in the left atria, and 7.26 ± 0.11 in the trachea, indicating that isoeugenodilol was a nonselective β-adrenoceptor blocker. In thoracic aorta experiments, isoeugenodilol also produced a competitive antagonism of norepinephrine-induced contraction with a pA2 value of 7.47 ± 0.45. In isolated atria of reserpinized rats, cumulative additions of isoeugenodilol and propranolol produced significantly cardiodepressant responses at high concentrations (10–5 M) and were without intrinsic sympathomimetic activity (ISA). In isolated rat thoracic aorta, isoeugenodilol more potently relaxed the contractions induced by norepinephrine (3 × 10–6 M) than those by high K+ (75 mM). The vasorelaxant effects of isoeugenodilol on norepinephrine-induced contractions were attenuated by pretreatment with tetraethylammonium (TEA) and glibenclamide, implying the involvement of K+ channel opening. In addition, isoeugenodilol inhibited norepinephrine-induced biphasic contraction; it affected the fast phase significantly more than the slow phase. Furthermore, the binding characteristics of isoeugenodilol and various β-adrenoceptor antagonists were evaluated in [3H]CGP-12177 binding to rat ventricle and lung tissues and [3H]prazosin binding to brain membranes. The ranking order of inhibition for [3H]CGP-12177 binding on β-adrenoceptor was propranolol > labetalol > isoeugenodilol, and that for [3H]prazosin binding to α-adrenoceptors was isoeugenodilol > labetalol. Furthermore, isoeugenodilol inhibited lipid peroxidation induced by Fe2+ and ascorbic acid with IC50 of 0.74 ± 0.03 mM, indicating that it possesses the antioxidant activity inherent in isoeugenol. In conclusion, isoeugenodilol was found to be a new generation α/β-adrenoceptor antagonist with vasorelaxant activity by inhibiting Ca2+ channel, receptor-mediated Ca2+ mobilization and by K+ channel opening, and to have additional potentially antioxidant effects. Drug Dev. Res. 51:29–42, 2000. © 2000 Wiley-Liss, Inc.